TY - JOUR
T1 - Ustekinumab is effective against small bowel lesions in Crohn’s disease
T2 - two case reports
AU - Murate, Kentaro
AU - Nakamura, Masanao
AU - Yamamura, Takeshi
AU - Maeda, Keiko
AU - Sawada, Tsunaki
AU - Mizutani, Yasuyuki
AU - Ishikawa, Eri
AU - Kakushima, Naomi
AU - Furukawa, Kazuhiro
AU - Ohno, Eizaburo
AU - Honda, Takashi
AU - Kawashima, Hiroki
AU - Ishigami, Masatoshi
AU - Fujishiro, Mitsuhiro
N1 - Publisher Copyright:
© 2020, Japanese Society of Gastroenterology.
PY - 2021/2
Y1 - 2021/2
N2 - We encountered two patients with Crohn’s disease (CD) for whom induction of ustekinumab was effective for the management of small intestinal lesions with stenosis. The first symptomatic CD case was a 40-year-old female with longitudinal ulcers in the small bowel found at double-balloon endoscopy. She was in a biologic-naïve condition. Her symptoms improved immediately after ustekinumab induction. We confirmed the condition of intestinal mucosa by double-balloon endoscopy. Deep ulcers remained open at 24 weeks and were scarred at 72 weeks. The second case was a 50-year-old male who failed to respond to treatment with anti-TNFα agents. The lumen was narrow caused by circumferential ulcer, and an endoscope could not pass the site before induction. The circumferential ulcer had been healed by ustekinumab induction, and an endoscope passed through at 72 weeks. These two cases support the therapeutic efficacy of ustekinumab in alleviating small bowel lesions in CD patients.
AB - We encountered two patients with Crohn’s disease (CD) for whom induction of ustekinumab was effective for the management of small intestinal lesions with stenosis. The first symptomatic CD case was a 40-year-old female with longitudinal ulcers in the small bowel found at double-balloon endoscopy. She was in a biologic-naïve condition. Her symptoms improved immediately after ustekinumab induction. We confirmed the condition of intestinal mucosa by double-balloon endoscopy. Deep ulcers remained open at 24 weeks and were scarred at 72 weeks. The second case was a 50-year-old male who failed to respond to treatment with anti-TNFα agents. The lumen was narrow caused by circumferential ulcer, and an endoscope could not pass the site before induction. The circumferential ulcer had been healed by ustekinumab induction, and an endoscope passed through at 72 weeks. These two cases support the therapeutic efficacy of ustekinumab in alleviating small bowel lesions in CD patients.
UR - https://www.scopus.com/pages/publications/85094136151
UR - https://www.scopus.com/pages/publications/85094136151#tab=citedBy
U2 - 10.1007/s12328-020-01242-0
DO - 10.1007/s12328-020-01242-0
M3 - Article
C2 - 33118129
AN - SCOPUS:85094136151
SN - 1865-7257
VL - 14
SP - 129
EP - 135
JO - Clinical Journal of Gastroenterology
JF - Clinical Journal of Gastroenterology
IS - 1
ER -